These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 37201112)

  • 1. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
    Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
    Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
    J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
    Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
    Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
    Tang Y; Zhou H; Xiang Y; Cui F
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
    Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
    Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.
    Jinato T; Anuntakarun S; Satthawiwat N; Chuaypen N; Tangkijvanich P
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):34. PubMed ID: 38183473
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Chen T; Ding R; Chen X; Lu Y; Shi J; Lü Y; Tang B; Zhang W; Ye C; Yuan M; Yang Z
    Bioengineered; 2021 Dec; 12(1):8233-8246. PubMed ID: 34592890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1
    Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
    Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.
    Zheng C; Lu F; Chen B; Yang J; Yu H; Wang D; Xie H; Chen K; Xie Y; Li J; Bo Z; Wang Y; Chen G; Deng T
    Cancer Sci; 2023 Dec; 114(12):4717-4731. PubMed ID: 37778742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.
    Shu W; Shanjian C; Jinpiao L; Qishui O
    Ann Hepatol; 2022; 27(2):100676. PubMed ID: 35093600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Lactic Acid Bacteria Anti-Hepatitis B Virus (HBV) Effect and Modulation of the Intestinal Microbiota in Fecal Cultures from HBV-Associated Hepatocellular Carcinoma Patients.
    Yang J; Gao H; Zhang T; Fan Y; Wu Y; Zhao X; Li Y; Wu L; Zhao H; Yang L; Zhong H; Li L; Xie X; Wu Q
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma.
    Huang JH; Wang J; Chai XQ; Li ZC; Jiang YH; Li J; Liu X; Fan J; Cai JB; Liu F
    Microbiol Spectr; 2022 Oct; 10(5):e0098322. PubMed ID: 36173308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model.
    Li X; Wu S; Du Y; Yang L; Li Y; Hong B
    Int J Antimicrob Agents; 2020 Jul; 56(1):106000. PubMed ID: 32360229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma.
    Bai Q; Li R; He X; Hong X; Yan Y; Zhao Z; Lin H; Tacke F; Engelmann C; Hu T
    Front Immunol; 2023; 14():1320414. PubMed ID: 38116005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project.
    Ling Z; Liu X; Cheng Y; Jiang X; Jiang H; Wang Y; Li L
    Sci Rep; 2015 Nov; 5():17098. PubMed ID: 26606973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.